Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock

NxStage Medical, Inc. (NASDAQ:NXTM) SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $24.88, for a total transaction of $87,080.00. Following the sale, the senior vice president now owns 13,770 shares in the company, valued at $342,597.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

NxStage Medical, Inc. (NASDAQ NXTM) traded up $0.46 during midday trading on Friday, hitting $25.23. 424,207 shares of the company were exchanged, compared to its average volume of 373,031. NxStage Medical, Inc. has a twelve month low of $20.45 and a twelve month high of $30.80. The company has a market cap of $1,650.00, a P/E ratio of -120.14 and a beta of -0.08.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. raised its holdings in shares of NxStage Medical by 4.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 307,037 shares of the medical device company’s stock valued at $7,440,000 after acquiring an additional 12,894 shares during the period. Bank of Montreal Can raised its holdings in shares of NxStage Medical by 15.5% during the fourth quarter. Bank of Montreal Can now owns 572,868 shares of the medical device company’s stock valued at $13,880,000 after acquiring an additional 77,082 shares during the period. CWM LLC raised its holdings in shares of NxStage Medical by 10.5% during the fourth quarter. CWM LLC now owns 123,149 shares of the medical device company’s stock valued at $2,984,000 after acquiring an additional 11,736 shares during the period. Athos Capital Ltd acquired a new stake in shares of NxStage Medical during the third quarter valued at approximately $579,000. Finally, Sterling Capital Management LLC raised its holdings in shares of NxStage Medical by 26.6% during the third quarter. Sterling Capital Management LLC now owns 81,767 shares of the medical device company’s stock valued at $2,257,000 after acquiring an additional 17,193 shares during the period. Institutional investors and hedge funds own 85.35% of the company’s stock.

A number of analysts recently commented on the stock. Canaccord Genuity reiterated a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a report on Tuesday, October 17th. Zacks Investment Research downgraded shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Northland Securities reiterated a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $30.25.

COPYRIGHT VIOLATION NOTICE: “Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/19/winifred-l-swan-sells-3500-shares-of-nxstage-medical-inc-nxtm-stock.html.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply